AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00580034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath Purged Non-myeloablative ASCT
Description: Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.~Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45.
Study NCT00580034 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Donor Apheresis
Description: Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
Study NCT02229305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Treatment
Description: Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
Study NCT02229305 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modular Approach to Therapy for Children
Description: Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita \& Weisz, 2010).
Study NCT02973204 — intervention group
Intervention type: DRUG
Intervention: Sorafenib
Study NCT02973204 — intervention group
Intervention type: PROCEDURE
Intervention: Radiofrequency ablation (RFA) or surgery
Description: Intended curative surgery or RFA
Study NCT02973204 — intervention group
Intervention type: DRUG
Intervention: Everolimus
Study NCT03039296 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic rhizotomy
Description: Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
Study NCT01463176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
Study NCT01006772 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid Ankle Foot Orthosis
Description: Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
Study NCT05106842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hydrotherapy
Description: Aquatic therapy was performed in a swimming pool (depth 125-140 cm, temperature 28-31°C) supervised by a physiotherapist. Patients were asked to kneel or sit to submerge both shoulders to perform exercises consisting of progressive passive and active motion of the shoulder for 4-6 weeks, then strengthening exercises in a swimming pool for 2-4 months.
Study NCT05106842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Land-based Therapy
Description: Land-based therapy was performed at a rehabilitation center supervised by a physiotherapist. Patients performed progressive passive and active-assisted motion of the shoulder for 4-6 weeks, then strengthening exercises for 2-4 months.
Study NCT04762914 — intervention group
Intervention type: OTHER
Intervention: Prehabilitation
Description: Prehabilitation is a multimodal and multidisciplinary person-centred perioperative approach involving supervised exercise training, nutritional education, management of polypharmacy and psychological advice.
Study NCT04157894 — intervention group
Intervention type: OTHER
Intervention: Standard long-lasting insecticidal net
Description: Interceptor® (BASF) contains a pyrethroid insecticide
Study NCT04157894 — intervention group
Intervention type: OTHER
Intervention: Chlorfenapyr insecticide treated net
Description: Interceptor® G2 (BASF) is an ITN containing two active ingredients: Alpha-cypermethrin, a pyrethroid insecticide, and chlorfenapyr, a pyrrole insecticide.
Study NCT04157894 — intervention group
Intervention type: OTHER
Intervention: Piperonyl butoxide long-lasting insecticidal net
Description: PermaNet®3.0 (Vestergaard) contains deltamethrin, a pyrethroid insecticide, and piperonyl butoxide, an insecticide synergist.
Study NCT02524769 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: conjugated estrogen
Description: 0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
Study NCT02663219 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
Study NCT00945321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant 165 mg
Description: Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
Study NCT00945321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: aprepitant 185 mg
Description: Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
Study NCT00945321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: fosaprepitant 150 mg
Description: Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
Study NCT00945321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: aprepitant with food
Description: Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
Study NCT03592797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laser acupuncture therapy
Description: Low level laser therapy to stimulate acupuncture points: Total 11 points will be used in the study. 7 points ST4, ST6, ST7, SI18, BL2, GB14, SJ17 located in the effected side of the face and will be stimulated ipsilateral. Two points ST36, LI4 located distally and will be stimulated bilateral.
Study NCT03592797 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture therapy
Description: Sham procedure of Low level laser therapy to stimulate acupuncture points is identical procedure as the intervention group. The same 11 points which mention above will be used, However, in the sham group the laser device will be deactivated and won't produce any laser beam irradiation.
Study NCT03117426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SYMFONY IOL
Description: IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
Study NCT03117426 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AT LISA tri 839MP IOL
Description: IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
Study NCT02246946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure
Description: To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
Study NCT02973204 — intervention group
Intervention type: DRUG
Intervention: Lanreotide
Description: Or other somatostatin analogues (SSTA), eg. Sandostatin
Study NCT04715204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Energy Oral Nutrition Supplement
Description: Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. Formula with caloric density of >1.2 kcal/mL is categorized as high energy ONS. This intervention has caloric density of 1.5 kcal/mL.
Study NCT04715204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Energy Oral Nutrition Supplement
Description: Oral Nutrition Supplement (ONS) or enteral formula is a formula intended to treat individuals who are unable to meet their nutritional requirements through oral diet alone. European Food Safety Authority described ONS as a formula with caloric density >0.9 kcal/mL. This intervention has caloric density of 1 kcal/mL and it is categorized as standard energy ONS.
Study NCT04715204 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula-75/Formula-100
Description: Formula-75/Formula-100 is a special therapeutic foods to treat children with severe acute malnutrition. WHO designed F75 as a starter formula for stabilization phase with 75 kcal/100 mL, then it is continued with F100 for rehabilitation phase with 100 kcal/100 mL Formula-75 and Formula-100 are made according to recipe from WHO. The ingredients are skimmed milk powder, coconut oil, and sugar. Mineral mix is added, i.e. 2 ml every 100 ml of formula.~The composition of F-75:~Skimmed milk 25 g, coconut oil 100 g, sugar 30 g, mineral mix 20 ml, add water to 1000 ml~The composition of F-100:~Skimmed milk 80 g, coconut oil 50 g, sugar 60 g, mineral mix 20 ml, add water to 1000 ml
Study NCT00845039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
Study NCT00845039 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance
Study NCT00845039 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 180 mg/m² every 14 days until disease progression or participant intolerance
Study NCT02078804 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: 20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
Study NCT03032107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1
Description: -T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
Study NCT03032107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: -Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
Study NCT04279236 — intervention group
Intervention type: OTHER
Intervention: Abbreviated Profile Hearing Aid Benefit (APHAB)
Description: An intervention in this study which is outside the routine clinical practice of the clinics is the APHAB questionnaire that will be completed by the subjects on 2 occasions.
Study NCT04279236 — intervention group
Intervention type: OTHER
Intervention: Glasgow Benefit Inventory (GBI)
Description: An intervention in this study which is outside the routine clinical practice of the clinics is the GBI questionnaire that will be completed by the subjects on 2 occasions.
Study NCT04279236 — intervention group
Intervention type: OTHER
Intervention: Additional follow-up visit
Description: There is an additional follow-up visit after surgery (compared to the routine clinical practice of the surgeons/clinics).
Study NCT01365169 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Participate in walking and/or strengthening program
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use accelerometers, blood pressure monitor, heart rate monitor, GPS device, and smart phone
Study NCT02246946 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Chest Physiotherapy
Description: To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
Study NCT02246946 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
Study NCT03964740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile App intervention
Description: The intervention is based on the interventional group subjects use of a mobile device with an ad-hoc designed application (called ASMATIC). This app permit them (in a daily basis) to record asthma control variables (peak-flow and presence of core symptoms), have daily reminders on their medication for asthma control and decision support for patient disease self-management; and contains advice on healthy lifestyle habits, including personalized diet recommendations based on clinical criteria and associated recipes. The device also permits the study subject to communicate with the hospital and for the study team to review potential issues of interest on the patient's asthma control parameters which might need an intervention such us additional in-person consultations
Study NCT00845039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 180 mg/m² every 14 days until disease progression or participant intolerance
Study NCT00845039 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-A12 (cixutumumab)
Description: IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance
Study NCT05338567 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Small intestine length measurement method
Description: Accuracy of digital 3D reconstruction for predicting small bowel length
Study NCT01256242 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Augment Rotator Cuff
Description: rhPDGF-BB and bovine collagen matrix
Study NCT01256242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Suture Repair
Description: standard suture repair
Study NCT03166085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PU-H71
Description: PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
Study NCT03166085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
Study NCT04580459 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARE Parenting Group Treatment
Description: The CARE parenting group treatment is a 12-session, 60-minute group mentalizing-focused intervention with 3 monthly parent-child sessions.
Study NCT04580459 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Treatment as Usual (TAU)
Description: Treatment as usual (TAU) involves typical child outpatient mental health services, such as individual child appointments and medication management.
Study NCT03802344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC2-01 cream
Description: MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%) cream
Study NCT03802344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cal/BDP combination
Description: Calcipotriene/betamethasone dipropionate, w/w 0,005%/0,064%
Study NCT03802344 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle cream
Study NCT01863173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol
Description: using B blocker in patient group
Study NCT01863173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo to control group
Study NCT00798460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: adefovir
Description: adefovir 10mg
Study NCT00798460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clevudine
Description: clevudine 30mg
Study NCT00798460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine
Description: lamivudine 100mg
Study NCT03900104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles
Description: Transcervical endometrial injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery. Injection performed with a trans-cervical catheter
Study NCT01611545 — intervention group
Intervention type: GENETIC
Intervention: Pharmacogenomics
Description: Utilizing pharmacogenomics to determine the most effective treatment
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use accelerometers, blood pressure monitor, weight scale, and smart phone
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use smart phone
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use CO monitor and smart phone
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use Fitbit, weight scale and iPhone- or web-based app for self-reported data
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03900104 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cervical injection of technetium 99 m-labeled human albumin colloid particles
Description: Cervical injection of technetium 99 m-labeled human albumin colloid particles, in 5 mL saline, 2 hours before surgery.
Study NCT04005560 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: no interventional study
Description: no interventional study
Study NCT01365169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Telemonitoring
Description: Use Fitbit and Actigraph
Study NCT04140903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Early transition to oral antibiotics
Description: Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
Study NCT04140903 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard treatment of intravenous antibiotics
Description: Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
Study NCT04334317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-071
Description: TAK-071 tablet.
Study NCT04334317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: TAK-071 placebo-matching tablet.
Study NCT02279381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
Study NCT02279381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care
Description: Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
Study NCT02279381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Essential Neonatal Care
Description: Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
Study NCT02279381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Essential Neonatal Care
Description: Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
Study NCT01415479 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
Study NCT01415479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
Study NCT01415479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quantitative
Description: Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
Study NCT01415479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default
Description: Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT.
Study NCT02839226 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AR/101
Study NCT02839226 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02305849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peficitinib
Description: oral tablet
Study NCT02305849 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet